JP2018507910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507910A5 JP2018507910A5 JP2017560893A JP2017560893A JP2018507910A5 JP 2018507910 A5 JP2018507910 A5 JP 2018507910A5 JP 2017560893 A JP2017560893 A JP 2017560893A JP 2017560893 A JP2017560893 A JP 2017560893A JP 2018507910 A5 JP2018507910 A5 JP 2018507910A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- odc1
- genotype
- pharmacotherapy
- drug therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000585693 Homo sapiens Mitochondrial 2-oxodicarboxylate carrier Proteins 0.000 claims 14
- 101001041245 Homo sapiens Ornithine decarboxylase Proteins 0.000 claims 14
- 102100021079 Ornithine decarboxylase Human genes 0.000 claims 14
- 238000002651 drug therapy Methods 0.000 claims 12
- 238000001050 pharmacotherapy Methods 0.000 claims 12
- 108700028369 Alleles Proteins 0.000 claims 10
- 238000012360 testing method Methods 0.000 claims 8
- 102000052812 Ornithine decarboxylases Human genes 0.000 claims 7
- 108700005126 Ornithine decarboxylases Proteins 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 229920000768 polyamine Polymers 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 102000004031 Carboxy-Lyases Human genes 0.000 claims 1
- 108090000489 Carboxy-Lyases Proteins 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- FJPAMFNRCFEGSD-UHFFFAOYSA-N eflornithine hydrochloride monohydrate Chemical compound O.Cl.NCCCC(N)(C(F)F)C(O)=O FJPAMFNRCFEGSD-UHFFFAOYSA-N 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 1
- 229960000894 sulindac Drugs 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- VLCYCQAOQCDTCN-ZCFIWIBFSA-N α-difluoromethylornithine Chemical compound NCCC[C@@](N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-ZCFIWIBFSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115413P | 2015-02-12 | 2015-02-12 | |
| US62/115,413 | 2015-02-12 | ||
| US201562154804P | 2015-04-30 | 2015-04-30 | |
| US62/154,804 | 2015-04-30 | ||
| PCT/US2016/017751 WO2016130918A1 (en) | 2015-02-12 | 2016-02-12 | Methods for treating neuroblastoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018507910A JP2018507910A (ja) | 2018-03-22 |
| JP2018507910A5 true JP2018507910A5 (https=) | 2019-03-22 |
Family
ID=56615061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560893A Pending JP2018507910A (ja) | 2015-02-12 | 2016-02-12 | 神経芽細胞腫を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20190046484A1 (https=) |
| EP (1) | EP3256117A4 (https=) |
| JP (1) | JP2018507910A (https=) |
| CA (1) | CA2976106A1 (https=) |
| HK (1) | HK1248133A1 (https=) |
| WO (1) | WO2016130918A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE040263T2 (hu) | 2012-10-29 | 2019-02-28 | Arizona Board Of Regents On Behalf Of Univ Of Arizona | Prediktív markerek poliamin-inhibitor rákterápiákhoz |
| WO2015195120A1 (en) | 2014-06-18 | 2015-12-23 | Arizona Board Of Regents On Behalf Of University Of Arizona | Carcinoma diagnosis and treatment based on odc1 genotype |
| CA2976106A1 (en) | 2015-02-12 | 2016-08-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating neuroblastoma |
| MA43114A (fr) | 2015-10-30 | 2018-09-05 | Cancer Prevention Pharmaceuticals Inc | Formulation combinée à dose fixe d'éflornithine et sulindac |
| CN109069462A (zh) | 2016-02-23 | 2018-12-21 | 癌症研究科技有限公司 | 缺乏至少两种非必需氨基酸的膳食产品 |
| IL314380A (en) * | 2016-10-06 | 2024-09-01 | Orbus Therapeutics Inc | Preparations for administration of aflornithine |
| EP3870158A4 (en) * | 2018-10-24 | 2022-08-10 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| CN114096240A (zh) * | 2019-05-17 | 2022-02-25 | 癌症预防制药股份有限公司 | 用于治疗家族性腺瘤性息肉病的方法 |
| JP2023530235A (ja) | 2020-06-03 | 2023-07-14 | フェス・セラピューティクス，インコーポレーテッド | 個別化された処置方法のための製剤 |
| WO2021247923A1 (en) | 2020-06-04 | 2021-12-09 | Faeth Therapeutics, Inc. | Personalized methods of treating cancer |
| WO2024105276A1 (en) | 2022-11-20 | 2024-05-23 | Universität Zürich | Combination of polyamine pathway inhibitor drug and proline/arginine diet restriction |
| US12605349B2 (en) | 2024-09-05 | 2026-04-21 | Orbus Therapeutics, Inc. | Methods of treating grade 3 astrocytoma |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309442A (en) | 1977-07-11 | 1982-01-05 | Merrell Toraude Et Compagnie | Method for controlling fertility in mammals |
| US4330559A (en) | 1977-07-11 | 1982-05-18 | Merrell-Toraude Et Cie | Method of treating benign prostatic hypertrophy |
| US4413141A (en) | 1977-07-11 | 1983-11-01 | Merrell Toraude Et Compagnie | 2-(Difluoromethyl)-2,5-diaminopentanoic acid |
| US4499072A (en) | 1982-11-29 | 1985-02-12 | Merrell Dow Pharmaceuticals Inc. | Process for treating diseases with ODC inhibitors |
| US4859452A (en) | 1986-01-17 | 1989-08-22 | Board Of Regents, The University Of Texas System | Methods for the reduction of difluoromethylornithine associated toxicity |
| US4925835A (en) | 1986-05-01 | 1990-05-15 | Sloan-Kettering Institute For Cancer Research | Aziridinyl putrescine containing compositions and their uses in treating prostate cancer |
| US5002879A (en) | 1986-05-06 | 1991-03-26 | Merrell Dow Pharmaceuticals | Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor |
| FR2706255B1 (fr) | 1993-06-17 | 1995-10-27 | Univ Rennes | Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques. |
| US5843929A (en) | 1996-03-22 | 1998-12-01 | Mayo Foundation For Medical Education And Research | Chemoprevention of metachronous adenomatous colorectal polyps |
| CA2241896A1 (en) | 1996-11-01 | 1998-05-14 | Ze'ev Shaked | Sustained release formulation containing dfmo |
| AU5526898A (en) | 1996-12-13 | 1998-07-03 | Ilex Oncology, Inc. | Isomeric pharmaceutical formulation containing dfmo for the treatment of cancer |
| CA2325080A1 (en) | 1998-03-28 | 1999-10-07 | The Regents Of The University Of California | Dfmo and sulindac combination in cancer chemoprevention |
| US7700568B2 (en) | 1998-06-30 | 2010-04-20 | Sloan-Kettering Institute For Cancer Research | Uses of DNA-PK |
| US6462229B1 (en) | 1998-09-23 | 2002-10-08 | Lonza Ltd. | Process for the preparation of (-)-α-(difluoromethyl)ornithine-monohydrochloride monohydrate |
| US6753422B2 (en) * | 1999-03-01 | 2004-06-22 | O'brien Thomas G. | Odc allelic analysis method for assessing carcinogenic susceptibility |
| CA2373931A1 (en) | 1999-05-17 | 2000-11-23 | Richard Love | Dfmo and celecoxib in combination for cancer chemoprevention and therapy |
| US6602910B2 (en) | 2000-03-07 | 2003-08-05 | Ilex Oncology, Inc. | D-enantiomer of DFMO and methods of use therefor |
| WO2001068076A2 (en) | 2000-03-07 | 2001-09-20 | Ilex Oncology, Inc. | D-enantiomer of dfmo and methods of use thereof for treating cancer |
| EP1351675A2 (en) | 2000-08-24 | 2003-10-15 | The Regents of the University of California | Alpha-difluoromethylornithine (dfmo) use in the human prostate |
| US6730809B2 (en) | 2001-08-29 | 2004-05-04 | Women First Healthcare, Inc. | Processes for the production of α-difluoromethyl ornithine (DFMO) |
| JP2005510524A (ja) | 2001-11-16 | 2005-04-21 | アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド | ポリアミン経路の調節による神経変性障害の治療 |
| EP1575584A4 (en) | 2002-11-29 | 2006-02-01 | Forest Laboratories | METHOD FOR THE TREATMENT OF ACUTE CHARACTERIZATION BY UNIFORM FORMING WITH IBUPROFEN AND OXYCODON |
| AU2005206277B2 (en) | 2004-01-22 | 2011-06-23 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
| US20100009929A1 (en) * | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| US9072778B2 (en) * | 2005-12-20 | 2015-07-07 | University Of Hawaii | Treatment regimen for N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors |
| BRPI0714937A2 (pt) | 2006-07-18 | 2013-03-26 | Horizon Therapeutics, Inc. | forma de dosagem unitÁria oral, e, uso de uma forma de dosagem unitÁria |
| FR2906808B1 (fr) | 2006-10-10 | 2012-10-05 | Univ Nantes | Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers |
| WO2009015981A2 (en) * | 2007-08-01 | 2009-02-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Treatment of pediatric tumors |
| US8283331B2 (en) | 2007-10-09 | 2012-10-09 | Children's Medical Center Corporation | Methods to regulate miRNA processing by targeting Lin-28 |
| US20100120727A1 (en) | 2008-11-12 | 2010-05-13 | Kyphia Pharmaceuticals, Inc. | Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof |
| EP2355775B1 (en) | 2008-12-08 | 2017-06-21 | The Procter and Gamble Company | Personal care composition in the form of an article having a hydrophobic surface-resident coating |
| PT2430452E (pt) | 2009-05-14 | 2014-09-30 | Univ Arizona State | Diagnóstico e tratamentos de carcinoma com base no genótipo odc1 |
| WO2010134047A2 (en) * | 2009-05-20 | 2010-11-25 | Ranbaxy Laboratories Limited | Liquid dosage forms of isotretinoin |
| US20110256161A1 (en) * | 2010-04-19 | 2011-10-20 | Aminex Therapeutics Inc. | Methods for enhancing immune response |
| CA2800557A1 (en) | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
| CA2799431A1 (en) | 2010-05-14 | 2011-11-17 | Cancer Prevention Pharmaceuticals, Inc. | Cancer prevention and treatment methods based on dietary polyamine content |
| EP3323830B1 (en) * | 2010-06-19 | 2023-08-23 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
| HUE040263T2 (hu) * | 2012-10-29 | 2019-02-28 | Arizona Board Of Regents On Behalf Of Univ Of Arizona | Prediktív markerek poliamin-inhibitor rákterápiákhoz |
| GB2513299A (en) * | 2013-03-12 | 2014-10-29 | Cellact Pharma Gmbh Biomedizinzentrum | Compounds for targeting cancer stem cells |
| RU2680267C2 (ru) | 2013-03-15 | 2019-02-19 | Мемориал Слоан Кеттеринг Кэнсер Сентер | Высокоаффинные антитела к gd2 |
| WO2015195120A1 (en) * | 2014-06-18 | 2015-12-23 | Arizona Board Of Regents On Behalf Of University Of Arizona | Carcinoma diagnosis and treatment based on odc1 genotype |
| CA2976106A1 (en) | 2015-02-12 | 2016-08-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating neuroblastoma |
| WO2017075576A1 (en) | 2015-10-30 | 2017-05-04 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
-
2016
- 2016-02-12 CA CA2976106A patent/CA2976106A1/en not_active Abandoned
- 2016-02-12 US US15/550,595 patent/US20190046484A1/en not_active Abandoned
- 2016-02-12 JP JP2017560893A patent/JP2018507910A/ja active Pending
- 2016-02-12 HK HK18107762.1A patent/HK1248133A1/zh unknown
- 2016-02-12 EP EP16749956.5A patent/EP3256117A4/en not_active Withdrawn
- 2016-02-12 WO PCT/US2016/017751 patent/WO2016130918A1/en not_active Ceased
-
2021
- 2021-01-13 US US17/147,697 patent/US20210378999A1/en not_active Abandoned
-
2023
- 2023-08-04 US US18/230,601 patent/US20240165063A1/en not_active Abandoned
-
2024
- 2024-12-23 US US18/999,227 patent/US12582625B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507910A5 (https=) | ||
| McQuay et al. | Randomized clinical trial of dexketoprofen/tramadol 25 mg/75 mg in moderate-to-severe pain after total hip arthroplasty | |
| Diemunsch et al. | Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery | |
| Hoy et al. | Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation | |
| Cosentino et al. | Phentermine and topiramate for the management of obesity: a review | |
| Laha et al. | Evaluation of antiemetic effect of intravenous palonosetron versus intravenous ondansetron in laparoscopic cholecystectomy: a randomized controlled trial | |
| Bionorica | Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis | |
| Zhao et al. | Chronic resveratrol treatment exerts antihyperalgesic effect and corrects co-morbid depressive like behaviors in mice with mononeuropathy: involvement of serotonergic system | |
| Kee | Phenylephrine infusions for maintaining blood pressure during spinal anesthesia for cesarean delivery: finding the shoe that fits | |
| Bateman et al. | Recent advances in COPD disease management with fixed-dose long-acting combination therapies | |
| Koh et al. | Postoperative pain and intravenous patient-controlled analgesia-related adverse effects in young and elderly patients: a retrospective analysis of 10,575 patients | |
| Bajwa et al. | Comparison of intrathecal clonidine and fentanyl in hyperbaric bupivacaine for spinal anesthesia and postoperative analgesia in patients undergoing lower abdominal surgeries | |
| Lee et al. | Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial | |
| JP2012526852A5 (https=) | ||
| Gupta et al. | Palonosetron, Ondansetron, and Granisetron for antiemetic prophylaxis of postoperative nausea and vomiting-A comparative evaluation | |
| Kraemer et al. | Pharmacologic management of acute pediatric pain | |
| Statler et al. | Ephedrine | |
| Maltais et al. | P250 Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD | |
| Majumdar et al. | Intravenous paracetamol infusion: Superior pain management and earlier discharge from hospital in patients undergoing palliative head-neck cancer surgery | |
| CN100418533C (zh) | 环加氧酶-2抑制剂和阿片剂的药物组合体 | |
| Fitzgerald et al. | Outpatient medication use and implications for dental care: guidance for contemporary dental practice | |
| Sturn et al. | Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients | |
| Gupta | Vasopressors and tight control of maternal blood pressure during cesarean delivery: A rocky alliance | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| Daniels et al. | Clinical efficacy and safety of tapentadol immediate release in the postoperative setting |